Pacemaker Implantation
Pacemaker Implantation - Related Videos
08:33
Porcine Cardiac Arrest Model Using an Implantable Defibrillator
0 Views •
2026
This protocol demonstrates the use of an implantable cardioverter-defibrillator (ICD) to reliably induce ventricular arrhythmias, perform internal cardioversion, and obtain intracardiac ECG recordings in a porcine model.
08:52
Generation of Murine Cardiac Pacemaker Cell Aggregates Based on ES-Cell-Programming in Combination with Myh6-Promoter-Selection
0 Views •
Cited by 13 •
2015
This protocol describes how to produce functional sinus nodal tissue from murine pluripotent stem cells (PSC). T-Box3 (TBX3) overexpression plus cardiac Myosin-heavy-chain (Myh6) promoter antibiotic selection leads to highly pure pacemaker cell aggregates. These “Induced-sinoatrial-bodies” (“iSABs”) contain over 80% pacemaker cells, show highly increased beating rates and are able to pace myocardium ex vivo.
05:54
Microbead Implantation in the Zebrafish Embryo
0 Views •
Cited by 8 •
2015
The zebrafish is an excellent model system for genetic and developmental studies. Bead implantation is a valuable tissue manipulation technique that can be used to interrogate developmental mechanisms by introducing alterations in local cellular environments. This protocol describes how to perform microbead implantation in the zebrafish embryo.
16:40
A New Single Chamber Implantable Defibrillator with Atrial Sensing: A Practical Demonstration of Sensing and Ease of Implantation
0 Views •
Cited by 5 •
2012
Dual-chamber implantable cardioverter-defibrillators (ICDs) may improve detection of atrial fibrillation as well as differentiation of tachycardias. However, this advantage is undermined by complications associated with the second electrode, which is required in conventional dual chamber devices. Therefore, BIOTRONIK has developed a new electrode called the LinoxSMART S DX that, when used in conjunction with the Lumax DX ICD, offers dual-chamber detection without the risks associated with the...
07:02
Animal Model of Implant-Associated Infections in Mice
0 Views •
2025
The present protocol describes a mouse model employing subcutaneous dorsal implantation to investigate implant-associated infections, enabling comprehensive investigation of pathophysiological mechanisms and supporting the development of diagnostic criteria with targeted therapeutic strategies.
FAQs
The system continuously senses the heart’s cardiac activity and compares the intrinsic rhythm with a programmed rate threshold. When the heart rate falls below that setting, the pulse generator directs an electrical impulse through the connected lead or leads. This responsive timing allows support to occur when slow rhythm is detected rather than delivering stimulation continuously.
The pulse generator serves as the electronic control unit, while the leads connect it with the heart and transmit information in both directions. Leads detect intrinsic cardiac activity and carry impulses when support is needed. Together, these components create a system that can respond to rhythm changes and provide clinicians with a basis for later device programming.
The programmed threshold determines when the device recognizes that the heart’s intrinsic rhythm has become too slow for the intended therapy. Its importance lies in coordinating device support with the patient’s own cardiac activity. Clinicians can tailor this setting during device management, helping align electrical stimulation with the rhythm problem being treated and the patient’s clinical needs.
Pacemaker therapy is not limited to the initial implantation. Device programming can be tailored during follow-up as clinicians assess cardiac function and the patient’s ongoing rhythm needs. This adjustability provides a way to refine how the system responds to intrinsic activity, while follow-up monitoring helps evaluate device performance and the continuing clinical effect of therapy.
The main clinical contexts include symptomatic bradycardia, conduction block, and some rhythm disorders. The presence of a slow or abnormal rhythm alone does not describe the full treatment goal; symptoms and the specific conduction or rhythm problem guide clinical use. When appropriate, therapy can improve heart rate and reduce symptoms associated with inadequate cardiac pacing.
Follow-up provides an opportunity to monitor cardiac function and assess whether device settings remain appropriate. Clinicians can review the system’s response to intrinsic cardiac activity and modify programming when needed. This continuing evaluation makes implantation part of an ongoing care process, rather than a one-time intervention, and supports individualized management of rhythm-related symptoms.